Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

10.1093/annonc/mdq784

Saved in:
Bibliographic Details
Main Authors: Yong, W.P., Goh, B.C., Soo, R.A., Toh, H.C., Ethirajulu, K., Wood, J., Novotny-Diermayr, V., Lee, S.C., Yeo, W.L., Chan, D., Lim, D., Seah, E., Lim, R., Zhu, J.
Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
Format: Article
Published: 2014
Subjects:
Histone deacetylase
Pharmacodynamics
Pharmacokinetics
Online Access:http://scholarbank.nus.edu.sg/handle/10635/117118
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
Description
Summary:10.1093/annonc/mdq784

Similar Items